HIGHLIGHTS
- who: PI et al. from the School of Sports Medicine and Health, Chengdu Sport University, Chengdu, China, School of Basic Medical Science, Chengdu have published the research: Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment, in the Journal: (JOURNAL) of 24/07/2017
- future: These findings might provide new directions for future research.
SUMMARY
The PI3K-Akt-mTOR signalling pathway is among the most common intracellular signalling pathways that are often abnormally activated in many human cancers and participate in different biological effects, such as cell cycle progression and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.